Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2006-1-10
pubmed:abstractText
To assess the efficacy and safety of pentoxifylline, a US Food and Drug Administration-approved drug, in patients with ALS treated with riluzole.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1526-632X
pubmed:author
pubmed:issnType
Electronic
pubmed:day
10
pubmed:volume
66
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
88-92
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:16401852-Adolescent, pubmed-meshheading:16401852-Adult, pubmed-meshheading:16401852-Aged, pubmed-meshheading:16401852-Aged, 80 and over, pubmed-meshheading:16401852-Amyotrophic Lateral Sclerosis, pubmed-meshheading:16401852-Double-Blind Method, pubmed-meshheading:16401852-Drug Interactions, pubmed-meshheading:16401852-Drug Therapy, Combination, pubmed-meshheading:16401852-Female, pubmed-meshheading:16401852-Humans, pubmed-meshheading:16401852-Male, pubmed-meshheading:16401852-Middle Aged, pubmed-meshheading:16401852-Muscle Weakness, pubmed-meshheading:16401852-Neuroprotective Agents, pubmed-meshheading:16401852-Pentoxifylline, pubmed-meshheading:16401852-Phosphodiesterase Inhibitors, pubmed-meshheading:16401852-Placebos, pubmed-meshheading:16401852-Riluzole, pubmed-meshheading:16401852-Treatment Failure
pubmed:year
2006
pubmed:articleTitle
Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.
pubmed:affiliation
Fédération des Maladies du Système Nerveux, Pavillon Paul Castaigne, AP-HP, Hôpital de la Salpétrière, Paris, France. vincent.meininger@psl.aphp.fr
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study